Long-term Safety and Efficacy Evaluation of Lunsekimig in Adult Participants With Chronic Rhinosinusitis With Nasal Polyps (CRSwNP) Who Completed a Previous Lunsekimig CRSwNP Clinical Study
← catalyst calendarNCT06914908 · readout in 1,624 d
Sponsored by Sanofi (industry) · SNY — their whole pipeline →.
Phase
Phase 2
Status
Enrolling by invitation
Study type
Interventional
Design
Na · None · Treatment
Enrollment
71estimated
Sites
24
Countries
Argentina, Belgium, Bulgaria +3
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2025-05-12 | actual | When the study began enrolling |
| Primary completion | 2031-01-29 | estimated | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | 2031-01-29 | estimated | The whole study's end, after follow-up |
| First posted | 2025-04-07 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-07-02 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Condition
- Chronic Rhinosinusitis With Nasal Polyps
Interventions
- Drug: Lunsekimig — also filed as SAR443765
- Drug: Mometasone furoate nasal spray (MFNS)
Primary outcome
what the primary-completion date above is the date OFIncidence of participants with treatment-emergent adverse events (TEAEs) including adverse events of special interest (AESI), and serious adverse events (SAEs)
measured From baseline to Week 148
Permalink · SNY's whole pipeline · Catalyst calendar · Every registered study · What changed